Other innovative lipid-modifying approaches include antisense oligonucleotides targeting apolipoprotein C3, angiopoietin-like protein 3, and lipoprotein(a) [Lp(a)]—such as pelacarsen and olpasiran—which demonstrate promising results in addressing genetically driven dyslipidemias. This evidence concerns the gene ANGPTL3 and metabolic syndrome.